This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Edelman, E. R. Articles by Danenberg, H. D. Search for Related Content PubMed PubMed Citation Articles by Edelman, E. R. Articles by Danenberg, H. D. Related Collections Related Article

(Circulation. 2003;108:6.)
© 2003 American Heart Association, Inc.

Editorials

Rapamycin for Cardiac Transplant Rejection and Vasculopathy

One Stone, Two Birds?

Elazer R. Edelman, MD, PhD; Haim D. Danenberg, MD

From the Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (E.R.E., H.D.D.); Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (E.R.E.); and Department of Cardiology, Hadassah University Hospital, Jerusalem, Israel (H.D.D.).

Correspondence to Elazer R. Edelman, MD, PhD, MIT Bldg 16-343, 77 Massachusetts Ave, Cambridge, MA 02139. E-mail ere@mit.edu

Key Words: Editorials • transplantation • rejection • vasculature

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Pour faire d’une pierre deux coups¹

Heart transplantation can now be routinely performed. Acute rejection has been significantly reduced, and the limitations to the use of this procedure include the availability of organs, chronic rejection, and a late reaction that is driven by a unique vasculopathy. Post-transplant vasculopathy (PTV) shares features with the lipoprotein-driven native atherosclerosis and proliferation-driven postangioplasty restenosis, but it has been thought to be more sensitive to immune forces. These distinctions are critical, for they dictate our choice of therapy. Hypercholesterolemia dictates treatments that lower lipoproteins or their effects; thrombotic events require antiplatelet agents, antithrombotics, and even agents that interfere with the clotting cascade; proliferative and migratory events can be inhibited by directed agents; and an immune disease would suggest use of immunosuppressants. To date, statins and immunosuppressants have been the mainstay of therapy for patients with heart transplants. These drugs were intended to simultaneously reduce rejection and post-transplant vasculopathy by limiting excessive lipid accumulation and exuberant inflammation. Recent reports, including the findings by Mancini et al² reported in this issue of Circulation, suggest that although reduction in rejection may directly follow from direct control of the immune response, the same is not true for the vasculopathy. Vascular disease in heart transplant patients is effectively controlled by an agent classified as an immunosuppressant but not because of immune modulation, rather because of antiproliferative effects.²

See p 48

Post-Transplant Vasculopathy

PTV is an aggressive and diffuse coronary arteriopathy that occurs in heart transplant recipients. With an annual incidence rate . . . [Full Text of this Article]

Related Article:

Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

Donna Mancini, Sean Pinney, Daniel Burkhoff, John LaManca, Silviu Itescu, Elizabeth Burke, Niloo Edwards, Mehmet Oz, and Andrew R. Marks
Circulation 2003 108: 48-53. [Abstract] [Full Text]

This article has been cited by other articles:

				W. Yang, J. Ge, H. Liu, K. Zhao, X. Liu, X. Qu, W. Li, Y. Huang, A. Sun, and Y. Zou Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model Cardiovasc Res, December 1, 2006; 72(3): 483 - 493. [Abstract] [Full Text] [PDF]

				B. S. Wiggins and S. Spinler Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes Journal of Pharmacy Practice, October 1, 2004; 17(5): 347 - 369. [Abstract] [PDF]

				S. Banai, S.D. Gertz, L. Gavish, M. Chorny, L. S. Perez, G. Lazarovichi, M. Ianculuvich, M. Hoffmann, M. Orlowski, G. Golomb, et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries Cardiovasc Res, October 1, 2004; 64(1): 165 - 171. [Abstract] [Full Text] [PDF]